Doximity's AI Usage Is Real-But the Q1 Earnings Verdict Still Depends on Monetization

Q1 revenue beat estimates, but EPS still left the debate open

Doximity's latest quarter was better than feared, but it did not settle the stock debate. The company reported 7.3% year-over-year revenue growth and beat consensus revenue by 3.24%. At the same time, EPS fell to $0.29 from $0.36, and Doximity reported 127 large customers versus an estimate of 129. That combination suggests real progress, but not yet the kind of all-around strength that fully reassures investors.

Why monetization matters more than another headline beat

The split in these numbers is what matters most. Subscription revenue rose 6.1% year over year, while total revenue grew 7.3%. That shows the core product is still improving, but not quickly enough to carry the entire investment case by itself. The large-customer miss was also small enough to argue either way: not a model-breaking result, but not a clean confirmation of broader monetization either.

My view is simple: Doximity does not need another merely "nice" quarter. It needs clearer evidence that doctors, accounts, and AI features are becoming bigger profit contributors over time.

Doximity's AI story is becoming a usage story

This quarter mattered because Doximity is starting to show a real product loop, not just AI excitement in theory.

Workflow adoption is the clearest sign of product fit

In Q4, Doximity reported over 800,000 active prescribers using workflow tools. Management also said nearly half of those users engaged with clinical AI, while prompts per user nearly doubled from January to April. That does not prove monetization, but it does suggest the tools are moving beyond the demo stage and into actual workflows.

That matters for two reasons:

• Stickier platform: When clinicians use messaging, fax, scheduling, and AI tools in one place, switching becomes less attractive.
• More room to monetize: If clinical AI is already reaching a large share of workflow users, the next question is whether that usage can translate into higher-paying products.

Adoption looks real, but the dollar lift is still uneven

The core argument between bulls and bears is no longer whether doctors are using Doximity's tools. It is whether that usage is translating into steadier spending per account and cleaner earnings power.

Proof of interest is not the same as paid expansion

Bulls can point to visible engagement. In the same full-year update, Doximity said it had over 800,000 active prescribers using workflow tools, with nearly half using clinical AI. Bears do not really dispute that. Their objection is narrower: usage alone does not prove broader, more durable monetization.

The clearest reminder of that limit came from customer metrics. Doximity reported 127 large customers, versus 129 estimated. That does not break the bullish case, but it does suggest monetization is still uneven enough to keep investors from giving the company a fully clean multiple.

The stronger cash flow numbers help, but they do not close the case

Earlier in the cycle, Doximity delivered Q1 revenue of $145.9 million, up 15%, along with operating cash flow of $62.1 million, up 51% year over year. That shows the business can convert activity into cash. But it also raises the bar for repeatability. If monetization were locking in broadly, investors would expect more consistent follow-through across quarters.

What to watch in the next quarter

For now, Doximity still looks like a watchlist-and-verify story. Investors need steadier clinical AI adoption, better large-customer growth, and some sign that earnings can improve from $0.29 EPS.

The scoreboard for the next quarter

A useful way to frame the next release is simple:

• Bullish read: AI and workflow usage keep deepening, large-customer trends improve, and earnings start to catch up.
• Bearish read: Usage remains healthy, but monetization still lags and the stock stays stuck in the same evaluation loop.

If usage keeps rising without a corresponding lift in paid expansion, Doximity may still look more like a compelling platform in development than a fully monetized growth story.